Combination Chemotherapy of Early and Advanced Murine P388 Leukaemia with Bouvardin, cis-Diamminedichloroplatinum and Vincristine
- 1 January 1984
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 41 (5) , 370-373
- https://doi.org/10.1159/000225855
Abstract
A comparative study of cytostatic combinations was carried out in early and advanced murine leukaemia P388 by using the new protein synthesis inhibitor bouvardin (BVD) along with the known anticancer drugs vincristine (VCR) and cis-diamminedichloroplatinum (DDP). The results indicate that the combination of BVD with DDP enhances the antineoplastic activity in comparison with single-agent therapy in early leukaemia. However, BVD could not indicate its superiority by way of tumour cell killing in three drug combinations, when administered with VCR and/or DDP, against advanced leukaemia.Keywords
This publication has 5 references indexed in Scilit:
- Induced Resistance in Leukaemia L1210 to Adriamycin and Its Cross-Resistance to Vincristine and BouvardinChemotherapy, 1982
- Effect of Bouvardin (NSC 259968) on the Growth Characteristics and Nucleic Acids and Protein Syntheses Profiles of P388 Leukemia CellsChemotherapy, 1981
- INVIVO CHARACTERISTICS OF RESISTANCE AND CROSS-RESISTANCE OF AN ADRIAMYCIN-RESISTANT SUBLINE OF P388 LEUKEMIA1978
- EFFECTS OF BOUVARDIN (NSC 259968), A CYCLIC HEXAPEPTIDE FROM BOUVARDIA-TERNIFOLIA, ON PROGRESSION CAPACITY OF CULTURED CHINESE-HAMSTER CELLS1978
- ESTIMATION OF THE ANTILEUKEMIC POTENCY OF THE ANTIMETABOLITE AMINOPTERIN, ADMINISTERED ALONE AND IN COMBINATION WITH CITROVORUM FACTOR OR FOLIC ACID1953